In the years 1962-1976, 168 children with nephroblastoma (Wilms Tumour) were treated in the Clinical Department of Child Oncology of the Institute of Mother and Child in Warsaw. In 150 cases, independently from surgery and radiotherapy, chemotherapy was performed. Our material was divided into 5 groups: a) without chemotherapy, b) chemotherapy with different drugs, c) chemotherapy with 1 course of Actinomycine D, d) chemotherapy with several courses of Actinomycine D, e) chemotherapy according to SIOP Trial. The results with reccurency free survival are as follows: a) 22,2%, b) 24,1%, c) 28,1%, d) 46,6%, e) 56,6%. In our material the best results were received with SIOP Trial chemotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Location of 7-Aminoactinomycin D in Micellar Medium Depends on Ionic Nature of the Surfactant Head Group.
Luminescence
February 2025
Department of Chemistry, University of Calcutta, Kolkata, India.
7-Aminoactinomycin D (7AAMD) is the fluorescent analogue of the anticancer drug actinomycin D (AMD). In order to overcome toxic side effects and enhanced bioavailability of 7AAMD, micellar drug carrier systems could be useful. We have used cationic (hexadecetyltrimethylammonium bromide [CTAB]), anionic (sodium dodecyl sulphate [SDS]) and non-ionic (t-octylphenoxypolyoxyethanol, Triton-X100 [TX 100]) surfactants to prepare micelle.
View Article and Find Full Text PDFTreatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies.
Cancer
January 2025
Division of Oncology, Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Background: In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II-IV FAWT. Four-year event-free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.
View Article and Find Full Text PDFPrimary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
Gynecol Oncol
January 2025
Department of Pathology of UFCSPA and Department of Pathology of Irmandade de Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Brazil.
Objective: To evaluate the efficacy of actinomycin D (ActD) as prophylactic chemotherapy (P-chem) in patients with high-risk complete hydatidiform mole (Hr-CHM) on progression to gestational trophoblastic neoplasia (GTN).
Methods: From 1996 to 2023, 426 Hr-CHMs were selected in a cohort of 1623 patients with gestational trophoblastic disease (GTD). From 1996 to 2023, 290 patients with Hr-CHMs received a single bolus dose of Act-D at the time of uterine evacuation (Hr-CHM P-chem group); 136 with the same risk factors did not receive P-chem (Hr-CHM control group).
Artificial intelligence can help individualize Wilms tumor treatment by predicting tumor response to preoperative chemotherapy.
Investig Clin Urol
January 2025
Department of Urology, Mansoura Urology and Nephrology Center, Mansoura University, Mansoura, Egypt.
Purpose: To create a computer-aided prediction (CAP) system to predict Wilms tumor (WT) responsiveness to preoperative chemotherapy (PC) using pre-therapy contrast-enhanced computed tomography (CECT).
Materials And Methods: A single-center database was reviewed for children <18 years diagnosed with WT and received PC between 2001 and 2021. Patients were excluded if pre- and post-PC CECT were not retrievable.
Late Ultra-High-Risk Recurrence of Gestational Trophoblastic Neoplasia Seven Years Posttreatment.
Cureus
December 2024
Obstetrics and Gynecology, University of Medicine and Pharmacy at Ho Chi Minh, Ho Chi Minh, VNM.
Gestational trophoblastic neoplasia (GTN) comprises a category of malignant or potentially malignant tumors that arise from gestational trophoblasts. Almost all cases of GTN experience a recurrence within the first year following treatment, although recurrences become rare after five years. Recurrent GTN tends to have a poor prognosis, primarily due to challenges in management, a high rate of relapse, and a low five-year survival rate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!